Stemcentrx Patents

Patent portfolio assigned to Stemcentrx (verified via public assignee records). Oncology biotech (cancer stem-cell therapeutics, lead asset Rova-T/anti-DLL3 ADC); acquired by AbbVie 2016 (~$5.8B) and effectively wound down after Rova-T's clinical failure. Holds many DLL3 antibody/ADC patents, originally assigned to Stemcentrx Inc, now AbbVie Stemcentrx LLC (e.g. US8986972B2). As a clinical-stage drug developer it had no commercial customers and no meaningfully sourceable 'direct competitors'.